NuvOx Therapeutics

NuvOx Therapeutics, Inc., of Tucson, Arizona, develops oxygen therapeutics for conditions where hypoxia matters. Its product candidate NanO2 is an intravenous emulsion of dodecafluoropentane whose nano-sized droplets turn to gas at body temperature and deliver oxygen to tissue. In oncology it is developed as a radiotherapy sensitiser, because hypoxic tumours respond less well to radiation. The company states that NanO2 has completed phase 1/2a trials in acute ischaemic stroke and in glioblastoma, that the FDA has allowed phase 2b trials in both, and that it received orphan drug designation for glioblastoma in 2015. The phase 2 RESTORE trial (NCT03862430) tests NanO2 with radiotherapy and temozolomide in newly diagnosed glioblastoma.